Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.

Abstract	Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.
Authors	B Lemieux, S Tartas, C Traulle, D Espinouse, C Thieblemont, F Bouafia, Q Alhusein, D Antal, G Salles, B Coiffier
Journal	Bone marrow transplantation (Bone Marrow Transplant) Vol. 33 Issue 9 Pg. 921-3 (May 2004) ISSN: 0268-3369 [Print] England
PMID	15034544 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antigens, CD20 Antineoplastic Agents Granulocyte Colony-Stimulating Factor Rituximab
Topics	Aged Antibodies, Monoclonal (pharmacology) Antibodies, Monoclonal, Murine-Derived Antigens, CD20 (chemistry) Antineoplastic Agents (pharmacology) Female Granulocyte Colony-Stimulating Factor (metabolism) Humans Lymphoma, Non-Hodgkin (therapy) Male Middle Aged Neutropenia (etiology) Neutrophils (metabolism) Rituximab Stem Cell Transplantation Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!